VNO:NYSEVornado Realty Trust Analysis
Data as of 2026-07-29 - not real-time
$40.65
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Vornado Realty Trust trades at a trailing PE of 11×, well below the industry average of 33×, and its DCF‑derived fair value of $40.5 is essentially in line with the current price of $40.65, suggesting a fairly valued position despite a modest -4.4% upside/downside metric. The REIT generates robust free cash flow (> $1.2 B) and pays a low‑payout dividend of 1.87%, indicating dividend sustainability, yet it carries a high debt‑to‑equity ratio of 126% and a forward PE of 162×, flagging earnings pressure ahead. Recent analyst sentiment turned negative with a Morgan Stanley downgrade to Underweight, and the upcoming Q2 earnings release on August 3 adds short‑term uncertainty.
Technically, the stock sits above its 20‑day and 50‑day SMAs and the 30‑day RSI of 61.5 signals continued bullish momentum, but the MACD histogram has turned negative and the price is flirting with a near‑term resistance at $41.58. Support sits at $37.68, providing a modest downside cushion, while the market’s “Extreme Greed” stance (F&G Index 84.5) could amplify short‑term volatility. Overall, the blend of attractive valuation, strong cash generation, and dividend safety supports a longer‑run buying case, but high leverage, sector‑specific office‑market headwinds, and the recent downgrade counsel caution in the near term.
Technically, the stock sits above its 20‑day and 50‑day SMAs and the 30‑day RSI of 61.5 signals continued bullish momentum, but the MACD histogram has turned negative and the price is flirting with a near‑term resistance at $41.58. Support sits at $37.68, providing a modest downside cushion, while the market’s “Extreme Greed” stance (F&G Index 84.5) could amplify short‑term volatility. Overall, the blend of attractive valuation, strong cash generation, and dividend safety supports a longer‑run buying case, but high leverage, sector‑specific office‑market headwinds, and the recent downgrade counsel caution in the near term.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 5/10
Key Factors
- Price approaching resistance at $41.58
- Bearish MACD histogram and recent downgrade
- Upcoming earnings release adds uncertainty
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong free cash flow covering debt obligations
- Sustainable dividend with low payout ratio
- Valuation near fair value with cheap PE relative to peers
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant upside potential if office demand recovers
- LEED‑certified portfolio positioning for ESG‑focused investors
- Attractive value metrics (low PE, reasonable PB) for patient capital
Key Metrics & Analysis
Financial Health
Revenue Growth-2.20%
Profit Margin42.89%
P/E Ratio11.1
ROE12.60%
ROA1.14%
Debt/Equity126.13
P/B Ratio1.6
Op. Cash Flow$1.3B
Free Cash Flow$1.2B
Industry P/E33.0
Technical Analysis
TrendBullish
RSI61.5
Support$37.68
Resistance$41.58
MA 20$39.54
MA 50$37.26
MA 200$33.27
MACDBearish
VolumeStable
Fear & Greed Index84.54
Valuation
Fair Value$40.50
Target Price$38.85
Upside/Downside-4.44%
GradeFair
TypeValue
Dividend Yield1.87%
Risk Assessment
Beta1.09
Volatility30.24%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.